| __timestamp | Exelixis, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 17986000 |
| Thursday, January 1, 2015 | 57305000 | 32480000 |
| Friday, January 1, 2016 | 116145000 | 68081000 |
| Sunday, January 1, 2017 | 159362000 | 169906000 |
| Monday, January 1, 2018 | 206366000 | 248932000 |
| Tuesday, January 1, 2019 | 228244000 | 354100000 |
| Wednesday, January 1, 2020 | 293355000 | 433300000 |
| Friday, January 1, 2021 | 401715000 | 583300000 |
| Saturday, January 1, 2022 | 459856000 | 752700000 |
| Sunday, January 1, 2023 | 542705000 | 887600000 |
| Monday, January 1, 2024 | 492128000 | 1007200000 |
Unlocking the unknown
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Exelixis, Inc. have shown significant growth in their Selling, General, and Administrative (SG&A) expenses, reflecting their strategic investments in operations and marketing. From 2014 to 2023, Neurocrine Biosciences saw a staggering 4,800% increase in SG&A expenses, peaking at nearly $888 million in 2023. Meanwhile, Exelixis experienced a 970% rise, reaching approximately $543 million in the same year. This upward trajectory highlights the companies' commitment to expanding their market presence and operational capabilities. As these biotech giants continue to innovate, their financial strategies will play a pivotal role in shaping their future success. Investors and industry analysts should keep a close eye on these trends to gauge the companies' long-term growth potential.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Exelixis, Inc.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: GSK plc vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Bausch Health Companies Inc.